Newbury Park, CA, United States of America

Francis Hall Martin

This inventor holds 28 USPTO granted patents and 5 published patent applications, plus 2 CIPO patents and 6 EPO patents, primarily in Monoclonal Antibodies. Top assignees: Amgen Inc., Medarex Inc., Amgen Fremont Inc.. Active years: 1999-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Francis Hall Martin. Retrieved from https://idiyas.com/inventor/francis-hall-martin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 28 (Patent Applications = 5)

% Patents Active = 71.4

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 2)

Average Co-Inventor Count = 4.4

ph-index = 12

Forward Citations = 367(Granted Patents)

Location History:

Thousand Oaks, CA (US) (2001 - 2006)
Newbury Park, CA (US) (1999 - 2017)

Company Filing History:

E. R. Squibb Sons, Inc.

patents

5. 2 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 1999-2017

Loading Chart...

Areas of Expertise:

Therapeutic Antibodies

IL-1R1

OPGL

Chimeric Toxin

Stem Cell Factor

Hematopoietic Progenitor

Cell Proliferation

Polynucleotides

FGF Family

Diagnostic Methods

Gene Transfer

Growth Factors

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9534053 - Therapeutic human anti-IL-1R1 monoclonal antibody (2017-01-03),

2. 8710203 - Therapeutic human anti-IL-1R1 monoclonal antibody (2014-04-29),

3. 8518407 - Therapeutic human anti-IL-1R1 monoclonal antibody (2013-08-27),

4. 8409578 - Methods for treating bone loss with antibodies to OPGL (2013-04-02),

5. 8236559 - Therapeutic human anti-IL-1R1 monoclonal antibody (2012-08-07),

6. 8058418 - Polynucleotides encoding heavy and light chains of antibodies to OPGL (2011-11-15),

7. 8043829 - DNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expression (2011-10-25),

8. 7910102 - Methods of using conjugated toxin peptide therapeutic agents (2011-03-22),

9. 7884054 - Methods for identifying functional antibodies (2011-02-08),

10. 7820623 - Conjugated toxin peptide therapeutic agents (2010-10-26),

11. 7438910 - Therapeutic human anti-IL1-R1 monoclonal antibody (2008-10-21),

12. 7364736 - Antibodies to OPGL (2008-04-29),

13. 7144731 - SCF antibody compositions and methods of using the same (2006-12-05),

14. 6967029 - Method for increasing hematopoietic progenitor cells by stem cell factor (2005-11-22),

15. 6852313 - Method of stimulating growth of melanocyte cells by administering stem cell factor (2005-02-08),

Title: Exploring the Innovative Contributions of Francis Hall Martin

Introduction

Francis Hall Martin, based in Newbury Park, California, has made significant contributions to the field of biomedicine through his impressive portfolio of 28 patents. His work focuses primarily on monoclonal antibodies, specifically those that target the interleukin-1 receptor type 1 (IL-1R1), paving the way for advancements in treatments for IL-1 mediated diseases.

Latest Patents

Among his latest patents, Martin has developed therapeutic human anti-IL-1R1 monoclonal antibodies. These innovative antibodies have been demonstrated to interact effectively with IL-1R1. His patents describe methods of treating diseases mediated by IL-1 through the administration of a pharmaceutically effective amount of these antibodies. Additionally, he has outlined novel methods for detecting the amount of IL-1R1 in biological samples using these specific antibodies, further enhancing diagnostic and therapeutic strategies.

Career Highlights

Throughout his career, Martin has been associated with prominent companies in the biotechnology sector, including Amgen Inc. and Amgen Fremont Inc. His work in these organizations has allowed him to contribute substantially to medical research and therapeutic development. His expertise in monoclonal antibodies has positioned him as a pivotal figure in the advancement of targeted therapies.

Collaborations

Martin has collaborated with esteemed colleagues in the field, including Krisztina M. Zsebo and Robert A. Bosselman. These professional relationships highlight the collaborative nature of innovation in biomedicine, where diverse expertise converges to address complex medical challenges.

Conclusion

Francis Hall Martin's pioneering work exemplifies the importance of innovation in healthcare, particularly through the development of antibody therapies for IL-1 mediated diseases. His extensive portfolio of patents serves as a testament to his commitment to advancing medical science and improving patient outcomes. As research continues to evolve, Martin's contributions will undoubtedly play a critical role in shaping future therapeutic strategies.

Profile summary based on public USPTO records.